A new NICVD study shows that nearly half of Pakistan’s heart attack patients are under 49, and 15% are under 40.
Doctors warn that diabetes, high blood pressure, obesity, smoking, and inactivity are causing more young people to suffer heart attacks.
The RIVAWAR trial, Pakistan’s largest study on a dangerous blood clot after heart attack (LVT), found that rivaroxaban, a locally made drug, works as well as the standard medicine warfarin — and clears clots faster in early weeks. Both drugs were safe, with no strokes reported.
Experts urge people to take symptoms like chest heaviness seriously and get an ECG quickly.
The new drug could lower costs and make treatment easier, as it doesn’t need frequent blood tests.
Early diagnosis and treatment could prevent thousands of strokes each year.
